Outcome of Stroke With Mild or Rapidly Improving Symptoms

Background and Purpose— Acute ischemic stroke with mild or rapidly improving symptoms is expected to result in good functional outcome, whether treated or not. Therefore, thrombolysis with its potential risks does not seem to be justified in such patients. However, recent studies indicate that the outcome is not invariably benign. Methods— We analyzed clinical and radiological data of patients with stroke who presented within 6 hours of stroke onset and did not receive thrombolysis because of mild or rapidly improving symptoms. Univariate and logistic regression analyses were performed to define predictors of clinical outcome. Results— One hundred sixty-two consecutive patients (110 men and 52 women) aged 63±13 years were included. The median National Institutes of Health Stroke Scale score on admission was 2 (range, 1 to 14). All patients presented within 6 hours of symptom onset. After 3 months, modified Rankin Scale score was ≤1 in 122 patients (75%), indicating a favorable outcome. Thirty-eight patients (23.5%) had an unfavorable outcome (modified Rankin Scale 2 to 5) and 2 patients (1.3%) had died. Baseline National Institutes of Health Stroke Scale score ≥10 points increased the odds of unfavorable outcome or death 16.9-fold (95% CI: 1.8 to 159.5; P<0.013), and proximal vessel occlusion increased the odds 7.13-fold (95% CI: 1.1 to 45.5; P<0.038). Conclusions— Seventy-five percent of patients with mild or rapidly improving symptoms will have a favorable outcome after 3 months. Therefore, a decision against thrombolysis seems to be justified in the majority of patients. However, selected patients, especially those with proximal vessel occlusions and baseline National Institutes of Health Stroke Scale scores ≥10 points, might derive a benefit from thrombolysis.

[1]  G. Schroth,et al.  Reasons to withhold intra-arterial thrombolysis in clinical practice , 2006, Journal of Neurology.

[2]  Jeffery R. Alger,et al.  Early MRI and outcomes of untreated patients with mild or improving ischemic stroke , 2006, Neurology.

[3]  A. Siegel,et al.  Good Outcomes in Ischemic Stroke Patients Treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms , 2006, Stroke.

[4]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[5]  Eric E. Smith,et al.  Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.

[6]  K Yaffe,et al.  Frontotemporal dementia progresses to death faster than Alzheimer disease , 2005, Neurology.

[7]  Robert Adams,et al.  Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. , 2005, Stroke.

[8]  J. Martí-Fàbregas,et al.  Reasons for exclusion from thrombolytic therapy following acute ischemic stroke , 2005, Neurology.

[9]  M. Hammer,et al.  Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. , 2004, Archives of neurology.

[10]  A. Demchuk,et al.  Mild Neurological Symptoms Despite Middle Cerebral Artery Occlusion , 2004, Stroke.

[11]  R. Grubb,et al.  Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.

[12]  À. Rovira,et al.  Prediction of Early Neurological Deterioration Using Diffusion- and Perfusion-Weighted Imaging in Hyperacute Middle Cerebral Artery Ischemic Stroke , 2002, Stroke.

[13]  G. Schroth,et al.  Intra-Arterial Thrombolysis in 100 Patients With Acute Stroke Due to Middle Cerebral Artery Occlusion , 2002, Stroke.

[14]  G Schlaug,et al.  Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility , 2001, Neurology.

[15]  P. Akins,et al.  Intra-arterial prourokinase for acute ischemic stroke. , 2000, JAMA.

[16]  A. Alexandrov,et al.  Deterioration following spontaneous improvement : sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. , 2000, Stroke.

[17]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[18]  D. Toni,et al.  Early spontaneous improvement and deterioration of ischemic stroke patients. A serial study with transcranial Doppler ultrasonography. , 1998, Stroke.

[19]  J. Grotta,et al.  Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.

[20]  L Bozzao,et al.  Acute stroke: usefulness of early CT findings before thrombolytic therapy. , 1997, Radiology.

[21]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[22]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[23]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.